Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ZKAB001 |
Synonyms | |
Therapy Description |
ZKAB001 is a monoclonal antibody targeting CD274 (PD-L1), which potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of tumor growth (PMID: 36469563). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ZKAB001 | ZKAB 001|ZKAB-001|Socazolimab|STIA1014|STI-A1014|STI A1014 | PD-L1/PD-1 antibody 122 | ZKAB001 is a monoclonal antibody targeting CD274 (PD-L1), which potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of tumor growth (PMID: 36469563). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | osteosarcoma | predicted - sensitive | ZKAB001 | Case Reports/Case Series | Actionable | In a Phase I/II trial, ZKAB001 treatment resulted in improved 6, 12, and 24-month event-free survival (100%) in osteosarcoma patients with CD274 (PD-L1) expression (TPS >/= 1%) compared to a 6-month EFS of 84.5% and 12 and 24-month EFS of 64.7% in patients without CD274 (PD-L1) expression (PMID: 36469563). | 36469563 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|